Closed System Transfer Devices Market by Type (Membrane-to-Membrane, Needleless), Technology (Diaphragm based, Compartmentalized, Filtration), Component, End User (Hospitals & Clinics, Oncology Centers), and Region (2022 - 2026)
[236 Pages Report] The closed system transfer devices (CSTDs) market is projected to reach USD 2,002 million by 2026 from USD 814 million in 2021, at a CAGR of 19.7% during the forecast period. The growth of this market can be attributed to the increasing demand of CSTDs to combat the harmful effects of cytotoxic or antineoplastic drugs, rising incidence of cancer and increasing emphasis on the implementation of occupational health and safety standards. However, the high cost of implementation of CSTDs, along with a lack of reimbursement for CSTDs is expected to restrain the growth of this market to a certain extent
To know about the assumptions considered for the study, Request for Free Sample Report
Impact of Covid-19 on Closed System Transfer Device Market
The outbreak of COVID-19 lead to the decrease in the demand of CSTDs during the first two quarters of 2020. Due to the virus containment norms and nationwide lockdowns, there were limited patient footfalls in hospitals, mostly related to COVID-19 and emergency cases. The elective medical procedures on hold thereby causing a negative shift in the demand of CSTDs. However, with the decline in the number of active COVID-19 cases coupled with the economic recovery in developed nations, further utilization of these devices may be expected in the near future.
Closed System Transfer Device Market Dynamics:
DRIVERS: Increasing use of CSTDs to combat harmful effects of cytotoxic and antineoplastic drugs
Antineoplastic drugs are widely used in the treatment of cancer and are considered as hazardous drugs.Healthcare workers involved in the preparation, transport, distribution, administration (pre- and post-administration), and disposal of these drugs are at extremely high risk. The National Institute for Occupational Safety and Health (NIOSH) recommends the use of CSTDs to eliminate the harmful effects caused by the exposure to harzadous substances that escape out of the system during drug preparation and administration. CSTDs act as a barrier and prevents the entry of contaminants prevent the transfer of contaminants from atmosphere to sterile environment. Owing to these advantages, CSTDs are increasingly being used in healthcare facilities to combat the harmful effects of hazardous drugs.
Chemotherapy, a widely adopted cancer treatment, uses one or more antineoplastic drugs, which destroy abnormal cells in patients. The use of closed system transfer devices (CSTDs) in conjunction with other safety precautions such as gloves, gowns, masks, and vented preparation hoods is an effective way to increase safety when preparing, transporting, administering, and disposing of hazardous drugs. With the increasing incidence of cancer and increasing adoption of chemotherapy treatments, the demand for CSTDs is expected to increase in the coming years.
The increasing number of oncology drug approvals
Currently, oncology drug development is a prominent area of interest for pharmaceutical companies. Advances in the understanding of cancer biology and therapeutic strategies have resulted in increasing drug applications and approvals. With the increasing number of indications for previously approved oncology drugs, the target patient population is expected to increase, which boosts the uptake of hazardous oncology drugs. Furthermore, new developments in oncology will lead to more treatment options and more safety issues with respect to new medicines. In addition to this, recent advances in clinical drug development, resulting from advances in the molecular understanding of cancer with associated targeted pharmacological interventions and the need to bring effective drugs efficiently, fuel innovation in oncology drug development. With the increasing number of oncology drug approvals, the need to use safety precautions, including CSTDs, is increasing; this is likely to grow the market.
RESTRAINTS: High cost of implementation of CSTDs and lack of reimbursement
Cost of closed system transfer device is one of the major constraint limiting its adoption in the healthcare facilities. Cost of a typical CSTD primarily depends upon factors like manufacturer, components used and drug that is to be administered. Moreover, since CSTDs are meant for single-use, the cost per unit is higher than regular syringers. The median price of CSTD ranges between USD8-12 per dose.
According to the regulatory guidelines, CSTDs are categorized as IV consumables. Its usage is not mandatory in European and other developing nations. Since, the use of these devices is absolutely voluntary in these countries, its reimbursement is unlikely. Hence, lack of standard guidelines further act as a hindrance for the adoption of these devices.
Lack of compliance with regulatory guidelines in developing countries
The use of CSTDs for handling hazardous drugs is not mandatory in some European, Asia Pacific, Latin American, Middle Eastern, and African countries. However, in the US, various regulatory bodies have issued guidelines for the safe handling of hazardous drugs and to reduce the potential risks of occupational exposure. However, compliance with these regulations is low. According to a white paper published by ICU Medical, the adoption of CSTDs in US hospitals reached 41% in 2014. Lack of awareness regarding the risks involved with hazardous drug handling is a major factor limiting the adoption of CSTDs. Many regulatory bodies and associations governing pharmacy practitioners require hard evidence in the form of casualties directly related to exposure before issuing any safety mandate. Unfortunately, the risks are subtle, and progress is slow. Often many years in the making, these developments are difficult to tie directly to exposure to hazardous drugs.
OPPORTUNITY: Increasing application of CSTDs in other therapeutic areas
CSTDs are majorly used to protect healthcare workers during the preparation and administration of antineoplastic drugs in chemotherapy. However, breath of application of these devices is increasing with increasing use in the treatment of various non-cancerous diseases such as rheumatoid arthritis, multiple sclerosis, psoriasis, and systemic lupus erythematosus. Non-cytotoxic drugs used to treat various conditions also fall under the category of hazardous drugs. Examples include Bacillus of Calmette, the Guerin strain of Mycobacterium Bovis (BCG), and monoclonal antibodies. The increase in the therapeutic applications of these drugs offers potential growth opportunities in the coming years.
CHALLENGES: Gaps with existing CSTDs
Currently available CSTDs do not offer foolproof solution to the exposure of hazardous drugs. These devices do not provide a system for the removal of hazardous residues present on the outer surface of the drug vials when they are received from the manufacturer. Moreover, existing CSTDs in the market have no component that enable secure transfer of hazardous drug directly from the ampoule to the syringe. In addition to this, there are no standardized procedure for testing the efficiency of CSTDs. These structural challenges limits the utilization and applications of CSTDs in the healthcare settings
Low awareness among nurses about CSTDs
Awareness among nurses and pharmacists about the lingering effects of cytotoxic drugs is still relatively low. Nurses, oncologists, and pharmacists are at high risk due to occupational exposure to hazardous drugs. Although the risks are well documented by various scientists and regulatory bodies, the adoption of protective measures is low in hospitals and oncology centers, mainly due to low hospital budgets and additional efforts required for assembly setup.
Many healthcare professionals often do not know about other routes of exposure, specifically when it comes to vapors and aerosols that can escape into the environment. Many believe that other protective measures, such as using personal protective equipment like aprons, gloves, head caps, clean rooms, and biological safety cabinets, are sufficient. The high cost of implementation of CSTDs, along with low awareness about the risks and benefits, poses a significant challenge for companies in this market.
Colour-to-colour alignment system is expected to witness fastest growth due to the high efficiency offered by the pressure equalization mechanism and low cost
On the basis of closing mechanism, the market is segmented into Luer-lock systems, color-to-color alignment systems, click-to-lock systems, and push-to-turn systems. In 2020, colour-to-colour alignment systems registered the high growth rate due to its unique structure that prevents leaks, spills, or the escape of vapors and aerosols. These devices equalize the pressure within the system when fluids are withdrawn or injected into vials. Moreover, the low cost of this system, along with its advantages, increased its adoption among pharmacists, oncologists, and nurses.
Membrane-to-membrane systems are extensively used for the preparation and administration of cytotoxic drugs
Based on device type, the market is segmented into membrane-to-membrane systems and needleless systems. In 2020, the membrane-to-membrane systems was the largest and highest growing segment in the CSTDs market. The large share and high growth of this segment can be attributed to its ease of operation and lower risk of contamination associated with double-membrane containment systems.
Diaphragm-based devices segment accounted for the largest share of closed system transfer devices market in 2020
Based on technology, the CSTDs market is segmented into diaphragm-based devices, compartmentalized devices, and air cleaning/filtration devices. In 2020, the diaphragm-based devices segment was the major revenue generating segment in the market. The large share of this segment is mainly due to the ease of operation and safety provided by these devices. This was followed by the compartmentalized devices segment which is expected to grow at the highest CAGR of 23.8% during the forecast period owing to its to lower cost.
Vial access devices segment accounted for the largest share of closed system transfer devices market in 2020
Based on components, the CSTDs market is segmented into vial access devices, syringe safety devices, bag/line access devices, and accessories. In 2020, the vial access devices segment accounted for the largest share of 33.08% of the market. The large share of this segment is mainly due to the increasing adoption of CSTD products and vial access devices by oncology nurses to transfer hazardous drugs from packaged vials to the infusion bag or the patient.
Hospitals & Clinics accounted for the largest share of closed system transfer devices market in 2020
Based on end users, the market is segmented into hospitals & clinics, oncology centers, and other end users. In 2020, hospitals & clinics accounted for the largest share of 84.41% of the CSTDs market. The large share and high growth of this segment are mainly due to the strong financial capabilities of hospitals for purchasing high-priced CSTDs, the large cancer patient pool, and the need to comply with regulatory guidelines.
North America accounted for the largest share of the closed system transfer devices market in 2020
In 2020, North America hels the largest share in the market. Factors driving the adoption of CSTDs in North America include easy accessibility to advanced technologies, high awareness about CSTD among oncologists, nurses, and pharmacists, the presence of many CSTD manufacturing players in this region, and the high incidence of cancer. However, the APAC market is expected to witness the highest CAGR of 22.1% during the forecast period. Factors supporting the growing use of CSTDs in this region include rising incidence of cancer, increasing demand for better healthcare services, and increasing focus of international players on emerging markets such as India and China.
.
Key Market Players :
The prominent players in the global market are Becton, Dickinson and Company (US), ICU Medical (US), B. Braun Melsungen (Germany), JMS (Japan), Equashield (US), Simplivia Healthcare (Israel), Corvida Medical (US), Yukon Medical (US), CODAN Medizinische Geräte (Germany), VICTUS (US), Caragen (US), and Baxter International.
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
Request Sample Scope of the Report
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
|
Report Metric |
Details |
|
Market Size Available for Years |
2019–2026 |
|
Base Year Considered |
2020 |
|
Forecast Period |
2021–2026 |
|
Forecast Unit |
Value (USD Million) |
|
Segments Covered |
By Closing Mechanism, Type, Component, Technology, End User and Region |
|
Countries Covered |
|
The research report categorizes closed system transfer device market into the following segments and sub-segments:
By Closing Mechanism
- Push-to-Lock System
- Click-to-Lock System
- Luer lock System
- Color-to-Color alignment System
By Type
- Membrane-to-Membrane systems
- Needleless Systems
By Component
- Vial access devices
- Syringe safety devices
- Bag/line access devices
- Accessories
By Technology
- Diaphragm-based devices
- Compartmentalized devices
- Air cleaning/filtration devices
By Country
- Asia Pacific
- Japan
- China
- India
- Rest of APAC
- North America
- US
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
- Latin America
- Middle East and Africa
Recent Developments:
- In January 2021, Simplivia Healthcare acquired 70% of Novame.d, a diagnostic company that develops and manufactures a range of diagnostic kits to meet evolving trends of home care.
- In November 2020, Equashield LLC. partnered with Syntronic Hospitalar to introduce Equashield’s products in Brazil.
- In May 2021, BD expanded its drug delivery devices segment by establishing a high-tech manufacturing facility in Zaragoza, Spain.
- In March 2021, Yukon Medical received US FDA clearance for Arisure closed system transfer device (CSTD) under the ONB product classification.
Frequently Asked Questions (FAQ):
Which are the top industry players in the closed system transfer device market?
The prominent players in the global market are Becton, Dickinson and Company (US), ICU Medical (US), B. Braun Melsungen (Germany), JMS (Japan), Equashield (US), Simplivia Healthcare (Israel), Corvida Medical (US), Yukon Medical (US), CODAN Medizinische Geräte (Germany), VICTUS (US), Caragen (US), and Baxter International (US).
What are the top trends in the closed system transfer device market?
Trends in closed system transfer devices market:
- Automated compounding of hazardous drugs using robotic systems
- Emerging technologies for rapid detection tests to facilitate routine monitoring and safe handling of hazardous drugs.
Which region is dominating in the closed system transfer device market?
In 2020, North America accounted for the largest share of the market. The market in North America is characterized by easy accessibility to advanced technologies, high awareness about CSTD among oncologists, nurses, and pharmacists, the presence of many CSTD manufacturing players in this region, and the high incidence and prevalence of cancer. However, the APAC market is expected to witness the highest CAGR of 22.1% during the forecast period.
Which is the leading device type in the closed system transfer device market?
Based on device type, the market is segmented into membrane-to-membrane systems and needleless systems. In 2020, the membrane-to-membrane systems segment accounted for the largest share of 71.0% of the CSTDs market. This segment is expected to reach USD 1,488 million by 2026 from USD 583 million in 2021, at a CAGR of 20.6%. The large share and high growth of this segment are attributed to their ease of operation and lower risk of contamination associated with double-membrane containment systems.
Which is the leading device technology of the closed system transfer device market?
Based on technology, the CSTDs market is segmented into diaphragm-based devices, compartmentalized devices, and air cleaning/filtration devices. In 2020, the diaphragm-based devices segment accounted for the largest share of 43.6% of the market. This segment is expected to reach USD 829 million by 2026 from USD 353 million in 2021, at a CAGR of 18.6%. The large share of this segment is mainly due to the ease of operation and safety provided by these devices. The compartmentalized devices segment is expected to grow at the highest CAGR of 23.8% during the forecast period due to their lower cost. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 30)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSION AND EXCLUSIONS
1.3 MARKET SCOPE
FIGURE 1 CLOSED SYSTEM TRANSFER DEVICES MARKET SEGMENTATION
FIGURE 2 MARKET, BY REGION
1.3.1 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
TABLE 1 STANDARD CURRENCY CONVERSION RATES
1.5 STAKEHOLDERS
2 RESEARCH METHODOLOGY (Page No. - 35)
2.1 RESEARCH DATA
FIGURE 3 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 4 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY-SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND-SIDE): BY END USER, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 8 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 9 REVENUE SHARE ANALYSIS ILLUSTRATION
FIGURE 10 REVENUE ANALYSIS OF THE TOP THREE PUBLIC COMPANIES (2020)
FIGURE 11 BOTTOM-UP APPROACH
FIGURE 12 TOP-DOWN APPROACH
FIGURE 13 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MARKET (2021–2026)
FIGURE 14 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 15 DATA TRIANGULATION METHODOLOGY
2.4 ASSUMPTIONS FOR THE STUDY
2.5 LIMITATIONS
2.5.1 METHODOLOGY-RELATED LIMITATIONS
2.6 RISK ASSESSMENT
TABLE 2 RISK ASSESSMENT: CLOSED SYSTEM TRANSFER DEVICES MARKET
3 EXECUTIVE SUMMARY (Page No. - 49)
FIGURE 16 CLOSED SYSTEM TRANSFER DEVICES MARKET, BY CLOSING MECHANISM, 2021 VS. 2026 (USD MILLION)
FIGURE 17 MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 18 CLOSED SYSTEM TRANSFER DEVICES MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
FIGURE 19 MARKET, BY COMPONENT, 2021 VS. 2026 (USD MILLION)
FIGURE 20 MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
FIGURE 21 GEOGRAPHIC SNAPSHOT: CLOSED SYSTEM TRANSFER DEVICES MARKET
4 PREMIUM INSIGHTS (Page No. - 54)
4.1 CLOSED SYSTEM TRANSFER DEVICES MARKET OVERVIEW
FIGURE 22 THE RISING INCIDENCE OF CANCER IS DRIVING THE GROWTH OF THE MARKET
4.2 ASIA PACIFIC: CLOSED SYSTEM TRANSFER DEVICES MARKET OVERVIEW
FIGURE 23 DIAPHRAGM-BASED DEVICES ACCOUNTED FOR THE LARGEST SHARE OF THE APAC MARKET IN 2020
4.3 CLOSED SYSTEM TRANSFER DEVICES MARKET: REGIONAL MIX
FIGURE 24 NORTH AMERICA TO DOMINATE THE MARKET THROUGHOUT THE FORECAST PERIOD
4.4 MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES
FIGURE 25 CHINA TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
4.5 MARKET: DEVELOPING VS. DEVELOPED MARKETS
FIGURE 26 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING THE FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 58)
5.1 INTRODUCTION
FIGURE 27 CLOSED SYSTEM TRANSFER DEVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.1.1 DRIVERS
5.1.1.1 Rising incidence of cancer
FIGURE 28 GLOBAL CANCER INCIDENCE (2008–2030)
TABLE 3 CANCER RATES, BY COUNTRY (2018)
TABLE 4 US: NEW CANCER CASES (2017–2020)
5.1.1.2 The increasing number of oncology drug approvals
TABLE 5 FDA APPROVALS: NOVEL PRESCRIPTION CANCER DRUGS IN 2018
5.1.1.3 Increasing use of CSTDs to combat the harmful effects of cytotoxic or antineoplastic drugs
5.1.1.4 Growing emphasis on the implementation of occupational health and safety standards
TABLE 6 LIST OF NATIONAL/LOCAL REGULATORY BODIES RECOMMENDING THE USE OF CSTDS FOR THE SAFE HANDLING OF HAZARDOUS DRUGS, BY COUNTRY
5.1.2 RESTRAINTS
5.1.2.1 High cost of implementation of CSTDs and lack of reimbursement
TABLE 7 AVERAGE ANNUAL COSTS ASSOCIATED WITH THE IMPLEMENTATION OF VARIOUS CSTD SYSTEMS (USD)
5.1.2.2 Lack of compliance with regulatory guidelines in developing countries
5.1.3 OPPORTUNITIES
5.1.3.1 Increasing application of CSTDs in other therapeutic areas
5.1.3.2 Increasing adoption in emerging economies due to rising healthcare expenditure
5.1.4 CHALLENGES
5.1.4.1 Gaps with existing CSTDs
TABLE 8 ISSUES, CHALLENGES, AND POTENTIAL SOLUTIONS REGARDING THE SAFE HANDLING OF HAZARDOUS DRUGS
5.1.4.2 Low awareness among nurses about CSTDs
5.2 PORTER’S FIVE FORCES ANALYSIS
TABLE 9 CLOSED SYSTEM TRANSFER DEVICES MARKET: PORTER’S FIVE FORCES ANALYSIS
5.2.1 THREAT OF NEW ENTRANTS
5.2.1.1 Growth in the medication delivery and management segment
5.2.1.2 Demand for safe drug compounding and handling devices
5.2.1.3 Highly concentrated market
5.2.1.4 Poor financing environment
5.2.1.5 Stringent regulatory environment
5.2.2 THREAT OF SUBSTITUTES
5.2.2.1 Unavailability of potential safe drug handling systems
5.2.2.2 Combination and integration of multiple technologies
5.2.3 BARGAINING POWER OF SUPPLIERS
5.2.3.1 Institutional technology providers
5.2.3.2 Substantially innovative technologies
5.2.3.3 Dysfunctional companies
5.2.4 BARGAINING POWER OF BUYERS
5.2.4.1 Few buyers and many sellers
5.2.4.2 Buy-out threat
5.2.4.3 Point of differentiation
5.2.5 INTENSITY OF COMPETITIVE RIVALRY
5.2.5.1 Highly concentrated industry
5.2.5.2 Similar funding source
5.3 INDUSTRY TRENDS
5.3.1 AUTOMATED COMPOUNDING OF HAZARDOUS DRUGS USING ROBOTIC SYSTEMS
5.3.2 EMERGING TECHNOLOGIES FOR RAPID DETECTION TESTS TO FACILITATE ROUTINE MONITORING AND SAFE HANDLING OF HAZARDOUS DRUGS
5.4 PRODUCT FEATURES AND PRICING ANALYSIS
TABLE 10 COMPARATIVE ANALYSIS OF COMMERCIALLY AVAILABLE CSTDS BASED ON PRODUCT FEATURES
5.5 UTILIZATION/ADOPTION OF CSTDS, BY REGION
TABLE 11 INTENSITY OF UTILIZATION/ADOPTION OF VARIOUS TYPES OF CSTDS,
5.6 REGULATORY GUIDELINES
TABLE 12 STRINGENCY OF REGULATIONS FOR THE ADOPTION OF CSTDS, BY REGION
5.6.1 REGULATIONS
5.6.2 NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH
TABLE 13 NIOSH CLASSIFICATION OF HAZARDOUS DRUGS
TABLE 14 NIOSH HAZARDOUS DRUG ADMINISTRATION RECOMMENDATIONS AND -REQUIREMENTS
5.6.3 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS
TABLE 15 NIOSH AND ASHP DEFINITIONS OF HAZARDOUS DRUGS
5.6.4 INTERNATIONAL SOCIETY OF ONCOLOGY PHARMACY PRACTITIONERS
5.7 REGULATORY ANALYSIS
5.8 ECOSYSTEM MAPPING
FIGURE 29 CLOSED SYSTEM TRANSFER DEVICES MARKET: ECOSYSTEM (2020)
5.9 VALUE CHAIN ANALYSIS
FIGURE 30 VALUE CHAIN ANALYSIS: CLOSED SYSTEM TRANSFER DEVICES
5.10 SUPPLY CHAIN ANALYSIS
FIGURE 31 SUPPLY CHAIN ANALYSIS: CLOSED SYSTEM TRANSFER DEVICES MARKET
5.11 PATENT ANALYSIS
FIGURE 32 PATENT ANALYSIS: CLOSED SYSTEM TRANSFER DEVICES MARKET
5.12 KEY MARKETS FOR IMPORT AND EXPORT (TRADE ANALYSIS FOR CLOSED SYSTEM TRANSFER DEVICES)
TABLE 16 IMPORT VALUE OF CLOSED SYSTEM TRANSFER DEVICES FOR TOP 10 COUNTRIES IN 2020
5.13 COVID-19 IMPACT ANALYSIS
5.13.1 COVID-19 HEALTH ASSESSMENT
5.13.2 COVID-19 ECONOMIC ASSESSMENT
5.13.3 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
FIGURE 33 CRITERIA IMPACTING THE GLOBAL ECONOMY
5.13.4 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN THE CLOSED SYSTEM TRANSFER DEVICES MARKET
5.14 YC-YCC SHIFT
FIGURE 34 YC-YCC SHIFT IN THE MARKET
6 CLOSED SYSTEM TRANSFER DEVICES MARKET, BY CLOSING MECHANISM (Page No. - 87)
6.1 INTRODUCTION
TABLE 17 TYPES OF CLOSING MECHANISMS IN THE CURRENTLY AVAILABLE CSTDS
TABLE 18 MARKET, BY CLOSING MECHANISM, 2019–2026 (USD MILLION)
6.2 LUER-LOCK SYSTEMS
6.2.1 LUER-LOCK MECHANISMS REDUCE THE RISK OF EXPOSURE, REQUIRE FEWER COMPONENTS, AND GENERATE LESS BIOHAZARDOUS WASTE—KEY ADVANTAGES DRIVING GROWTH
TABLE 19 LUER-LOCK MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.3 PUSH-TO-TURN SYSTEMS
6.3.1 HIGH ADOPTION OF PHASEAL, A PIONEER IN THE CSTD MARKET— A KEY MARKET DRIVER
TABLE 20 PUSH-TO-TURN MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.4 CLICK-TO-LOCK SYSTEMS
6.4.1 THE USER-FRIENDLY NATURE OF CLICK-TO-LOCK MECHANISMS DRIVES THEIR ADOPTION AMONG END USERS
TABLE 21 CLICK-TO-LOCK MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.5 COLOR-TO-COLOR ALIGNMENT SYSTEMS
6.5.1 LOW SYSTEM COST, ALONG WITH THE ADVANTAGES OFFERED, INCREASES THE ADOPTION OF THESE SYSTEMS AMONG PHARMACISTS, ONCOLOGISTS, AND NURSES
TABLE 22 COLOR-TO-COLOR ALIGNMENT MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7 CLOSED SYSTEM TRANSFER DEVICES MARKET, BY TYPE (Page No. - 93)
7.1 INTRODUCTION
TABLE 23 MARKET, BY TYPE, 2019–2026 (USD MILLION)
7.2 MEMBRANE-TO-MEMBRANE SYSTEMS
7.2.1 MEMBRANE-TO-MEMBRANE SYSTEMS PROVIDE A DOUBLE LAYER OF PROTECTION FOR THE SAFE TRANSFER OF HAZARDOUS DRUGS
TABLE 24 LEADING MANUFACTURERS OF MEMBRANE-TO-MEMBRANE SYSTEMS
TABLE 25 MEMBRANE-TO-MEMBRANE SYSTEMS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.3 NEEDLELESS SYSTEMS
7.3.1 CHEMOLOCK IS THE FIRST FDA-APPROVED NEEDLELESS CSTD SYSTEM
TABLE 26 LEADING MANUFACTURERS OF NEEDLELESS SYSTEMS
TABLE 27 NEEDLELESS SYSTEMS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8 CLOSED SYSTEM TRANSFER DEVICES MARKET, BY COMPONENT (Page No. - 97)
8.1 INTRODUCTION
TABLE 28 MARKET, BY COMPONENT,2019–2026 (USD MILLION)
8.2 VIAL ACCESS DEVICES
8.2.1 INCREASING REGULATORY COMPLIANCE TO DRIVE THE ADOPTION OF VIAL ACCESS DEVICES IN HOSPITALS & ONCOLOGY CENTERS
TABLE 29 VIAL ACCESS COMPONENTS FOR CLOSED SYSTEM TRANSFER DEVICES
TABLE 30 MARKET FOR VIAL ACCESS DEVICES, BY COUNTRY, 2019–2026 (USD MILLION)
8.3 SYRINGE SAFETY DEVICES
8.3.1 ADVANTAGES SUCH AS EASE OF USE AND LEAK PREVENTION ARE DRIVING THE ADOPTION OF THESE DEVICES GLOBALLY
TABLE 31 SYRINGE SAFETY COMPONENTS FOR CLOSED SYSTEM TRANSFER DEVICES
TABLE 32 MARKET FOR SYRINGE SAFETY DEVICES, BY COUNTRY, 2019–2026 (USD MILLION)
8.4 BAG/LINE ACCESS DEVICES
8.4.1 HIGH COMPATIBILITY OF BAG/LINE ACCESS DEVICES DRIVES MARKET GROWTH
TABLE 33 BAG/LINE ACCESS COMPONENTS FOR CLOSED SYSTEM TRANSFER DEVICES
TABLE 34 MARKET FOR BAG/LINE ACCESS DEVICES, BY COUNTRY, 2019–2026 (USD MILLION)
8.5 ACCESSORIES
8.5.1 MAJOR CSTDS REQUIRE DEDICATED ADMINISTRATION SETS, WHICH DRIVES GROWTH IN THE ACCESSORIES MARKET
TABLE 35 ACCESSORIES FOR CLOSED SYSTEM TRANSFER DEVICES
TABLE 36 MARKET FOR ACCESSORIES, BY COUNTRY, 2019–2026 (USD MILLION)
9 CLOSED SYSTEM TRANSFER DEVICES MARKET, BY TECHNOLOGY (Page No. - 107)
9.1 INTRODUCTION
TABLE 37 MARKET, BY TECHNOLOGY,2019–2026 (USD MILLION)
9.2 DIAPHRAGM-BASED DEVICES
9.2.1 DIAPHRAGM-BASED DEVICES DOMINATE THE MARKET DUE TO THE EASE OF USE & SAFETY PROVIDED DURING THE HANDLING OF HAZARDOUS DRUGS
TABLE 38 DIAPHRAGM-BASED DEVICES AVAILABLE IN THE MARKET
TABLE 39 DIAPHRAGM-BASED MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
9.3 COMPARTMENTALIZED DEVICES
9.3.1 COMPARTMENTALIZED DEVICES TO WITNESS THE HIGHEST GROWTH IN THE MARKET DURING THE FORECAST PERIOD
TABLE 40 COMPARTMENTALIZED DEVICES AVAILABLE IN THE MARKET
TABLE 41 COMPARTMENTALIZED MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
9.4 AIR CLEANING/FILTRATION DEVICES
9.4.1 AIR CLEANING DEVICES INCORPORATE AN ACTIVATED CARBON OR HYDROPHOBIC FILTER TO HELP REDUCE THE OUTFLOW OF CONTAMINANTS
TABLE 42 AIR CLEANING/FILTRATION DEVICES AVAILABLE IN THE MARKET
TABLE 43 AIR CLEANING/FILTRATION MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
10 CLOSED SYSTEM TRANSFER DEVICES MARKET, BY END USER (Page No. - 112)
10.1 INTRODUCTION
TABLE 44 MARKET, BY END USER, 2019–2026 (USD MILLION)
10.2 HOSPITALS & CLINICS
10.2.1 HOSPITALS FORM THE LARGEST END-USER SEGMENT OF THE MARKET
TABLE 45 MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2019–2026 (USD MILLION)
10.3 ONCOLOGY CENTERS
10.3.1 INCREASING REGULATORY MANDATES TO DRIVE THE ADOPTION OF CSTDS IN ONCOLOGY CENTERS & CLINICS
TABLE 46 MARKET FOR ONCOLOGY CENTERS, BY COUNTRY, 2019–2026 (USD MILLION)
10.4 OTHER END USERS
TABLE 47 MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)
11 CLOSED SYSTEM TRANSFER DEVICES MARKET, BY REGION (Page No. - 117)
11.1 INTRODUCTION
FIGURE 35 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
TABLE 48 CLOSED SYSTEM TRANSFER DEVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 36 NORTH AMERICA: MARKET SNAPSHOT
TABLE 49 NORTH AMERICA: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 50 NORTH AMERICA: MARKET, BY CLOSING MECHANISM, 2019–2026 (USD MILLION)
TABLE 51 NORTH AMERICA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 52 NORTH AMERICA: MARKET, BY COMPONENT, 2019–2026 (USD MILLION)
TABLE 53 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 54 NORTH AMERICA: MARKET, BY END USER, 2019–2026 (USD MILLION)
11.2.1 US
11.2.1.1 US dominates the North American market primarily due to the presence of leading CSTD manufacturing companies & the high burden of cancer
TABLE 55 US: KEY MACROINDICATORS
TABLE 56 US: CLOSED SYSTEM TRANSFER DEVICES MARKET, BY CLOSING MECHANISM, 2019–2026 (USD MILLION)
TABLE 57 US: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 58 US: MARKET, BY COMPONENT, 2019–2026 (USD MILLION)
TABLE 59 US: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 60 US: MARKET, BY END USER, 2019–2026 (USD MILLION)
11.2.2 CANADA
11.2.2.1 Increasing prevalence of cancer to drive the growth of the Canadian market
TABLE 61 CANADA: KEY MACROINDICATORS
TABLE 62 CANADA: CLOSED SYSTEM TRANSFER DEVICES MARKET, BY CLOSING MECHANISM, 2019–2026 (USD MILLION)
TABLE 63 CANADA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 64 CANADA: MARKET, BY COMPONENT, 2019–2026 (USD MILLION)
TABLE 65 CANADA: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 66 CANADA: MARKET, BY END USER, 2019–2026 (USD MILLION)
11.3 EUROPE
FIGURE 37 EUROPE: CLOSED SYSTEM TRANSFER DEVICES MARKET SNAPSHOT
TABLE 67 EUROPE: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 68 EUROPE: MARKET, BY CLOSING MECHANISM, 2019–2026 (USD MILLION)
TABLE 69 EUROPE: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 70 EUROPE: MARKET, BY COMPONENT, 2019–2026 (USD MILLION)
TABLE 71 EUROPE: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 72 EUROPE: MARKET, BY END USER, 2019–2026 (USD MILLION)
11.3.1 GERMANY
11.3.1.1 Germany to witness the highest growth in the European market
TABLE 73 GERMANY: KEY MACROINDICATORS
TABLE 74 GERMANY: CLOSED SYSTEM TRANSFER DEVICES MARKET, BY CLOSING MECHANISM, 2019–2026 (USD MILLION)
TABLE 75 GERMANY: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 76 GERMANY: MARKET, BY COMPONENT, 2019–2026 (USD MILLION)
TABLE 77 GERMANY: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 78 GERMANY: MARKET, BY END USER, 2019–2026 (USD MILLION)
11.3.2 UK
11.3.2.1 High cost of CSTDs to restrain the market growth
TABLE 79 UK: KEY MACROINDICATORS
TABLE 80 UK: CLOSED SYSTEM TRANSFER DEVICES MARKET, BY CLOSING MECHANISM, 2019–2026 (USD MILLION)
TABLE 81 UK: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 82 UK: MARKET, BY COMPONENT, 2019–2026 (USD MILLION)
TABLE 83 UK: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 84 UK: MARKET, BY END USER, 2019–2026 (USD MILLION)
11.3.3 FRANCE
11.3.3.1 High cancer prevalence and the high healthcare expenditure in the country to drive market growth in France
TABLE 85 FRANCE: KEY MACROINDICATORS
TABLE 86 FRANCE: CLOSED SYSTEM TRANSFER DEVICES MARKET, BY CLOSING MECHANISM, 2019–2026 (USD MILLION)
TABLE 87 FRANCE: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 88 FRANCE: MARKET, BY COMPONENT, 2019–2026 (USD MILLION)
TABLE 89 FRANCE: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 90 FRANCE: MARKET, BY END USER, 2019–2026 (USD MILLION)
11.3.4 ITALY
11.3.4.1 Increasing geriatric population and the subsequent increase in the prevalence of cancer to drive the market for closed system transfer devices in Italy
TABLE 91 ITALY: KEY MACROINDICATORS
TABLE 92 ITALY: CLOSED SYSTEM TRANSFER DEVICES MARKET, BY CLOSING MECHANISM, 2019–2026 (USD MILLION)
TABLE 93 ITALY: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 94 ITALY: MARKET, BY COMPONENT, 2019–2026 (USD MILLION)
TABLE 95 ITALY: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 96 ITALY: MARKET, BY END USER, 2019–2026 (USD MILLION)
11.3.5 SPAIN
11.3.5.1 Lack of specific regulations about CSTDs is restraining the growth of this market
TABLE 97 SPAIN: KEY MACROINDICATORS
TABLE 98 SPAIN: CLOSED SYSTEM TRANSFER DEVICES MARKET, BY CLOSING MECHANISM, 2019–2026 (USD MILLION)
TABLE 99 SPAIN: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 100 SPAIN: MARKET, BY COMPONENT, 2019–2026 (USD MILLION)
TABLE 101 SPAIN: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 102 SPAIN: MARKET, BY END USER, 2019–2026 (USD MILLION)
11.3.6 REST OF EUROPE
TABLE 103 ROE: CLOSED SYSTEM TRANSFER DEVICES MARKET, BY CLOSING MECHANISM, 2019–2026 (USD MILLION)
TABLE 104 ROE: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 105 ROE: MARKET, BY COMPONENT, 2019–2026 (USD MILLION)
TABLE 106 ROE: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 107 ROE: MARKET, BY END USER, 2019–2026 (USD MILLION)
11.4 ASIA PACIFIC
FIGURE 38 ASIA PACIFIC: CLOSED SYSTEM TRANSFER DEVICES MARKET SNAPSHOT
TABLE 108 APAC: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 109 APAC: MARKET, BY CLOSING MECHANISM, 2019–2026 (USD MILLION)
TABLE 110 APAC: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 111 APAC: MARKET, BY COMPONENT, 2019–2026 (USD MILLION)
TABLE 112 APAC: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 113 APAC: MARKET, BY END USER, 2019–2026 (USD MILLION)
11.4.1 JAPAN
11.4.1.1 Japan to dominate the APAC CSTDs market
TABLE 114 JAPAN: KEY MACROINDICATORS
TABLE 115 JAPAN: CLOSED SYSTEM TRANSFER DEVICES MARKET, BY CLOSING MECHANISM, 2019–2026 (USD MILLION)
TABLE 116 JAPAN: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 117 JAPAN: MARKET, BY COMPONENT, 2019–2026 (USD MILLION)
TABLE 118 JAPAN: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 119 JAPAN: MARKET, BY END USER, 2019–2026 (USD MILLION)
11.4.2 CHINA
11.4.2.1 The large patient pool provides significant growth opportunities in China
TABLE 120 CHINA: KEY MACROINDICATORS
TABLE 121 CHINA: CLOSED SYSTEM TRANSFER DEVICES MARKET, BY CLOSING MECHANISM, 2019–2026 (USD MILLION)
TABLE 122 CHINA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 123 CHINA: MARKET, BY COMPONENT, 2019–2026 (USD MILLION)
TABLE 124 CHINA: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 125 CHINA: MARKET, BY END USER, 2019–2026 (USD MILLION)
11.4.3 INDIA
11.4.3.1 Low manufacturing costs and skilled workforce are attracting outsourcing and investment to India
TABLE 126 INDIA: KEY MACROINDICATORS
TABLE 127 INDIA: CLOSED SYSTEM TRANSFER DEVICES MARKET, BY CLOSING MECHANISM, 2019–2026 (USD MILLION)
TABLE 128 INDIA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 129 INDIA: MARKET, BY COMPONENT, 2019–2026 (USD MILLION)
TABLE 130 INDIA: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 131 INDIA: MARKET, BY END USER, 2019–2026 (USD MILLION)
11.4.4 REST OF APAC
TABLE 132 ROAPAC: CLOSED SYSTEM TRANSFER DEVICES MARKET, BY CLOSING MECHANISM, 2019–2026 (USD MILLION)
TABLE 133 ROAPAC: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 134 ROAPAC: MARKET, BY COMPONENT, 2019–2026 (USD MILLION)
TABLE 135 ROAPAC: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 136 ROAPAC: MARKET, BY END USER, 2019–2026 (USD MILLION)
11.5 LATIN AMERICA
11.5.1 RISING CANCER INCIDENCE TO DRIVE MARKET GROWTH IN LATAM
TABLE 137 LATIN AMERICA: CLOSED SYSTEM TRANSFER DEVICES MARKET, BY CLOSING MECHANISM, 2019–2026 (USD MILLION)
TABLE 138 LATIN AMERICA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 139 LATIN AMERICA: MARKET, BY COMPONENT, 2019–2026 (USD MILLION)
TABLE 140 LATIN AMERICA: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 141 LATIN AMERICA: MARKET, BY END USER, 2019–2026 (USD MILLION)
11.6 MIDDLE EAST AND AFRICA
11.6.1 MEA MARKET TO GROW AT A SLOWER RATE THAN LATIN AMERICA
TABLE 142 MIDDLE EAST & AFRICA: CLOSED SYSTEM TRANSFER DEVICES MARKET, BY CLOSING MECHANISM, 2019–2026 (USD MILLION)
TABLE 143 MIDDLE EAST & AFRICA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 144 MIDDLE EAST & AFRICA: MARKET, BY COMPONENT, 2019–2026 (USD MILLION)
TABLE 145 MIDDLE EAST & AFRICA: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 146 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2019–2026 (USD MILLION)
12 COMPETITIVE LANDSCAPE (Page No. - 164)
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
FIGURE 39 OVERVIEW OF STRATEGIES ADOPTED BY MAJOR PLAYERS IN THE CLOSED SYSTEM TRANSFER DEVICE MARKET
12.3 REVENUE SHARE ANALYSIS
12.3.1 REVENUE ANALYSIS FOR KEY PLAYERS IN THE CLOSED SYSTEM TRANSFER DEVICES MARKET
FIGURE 40 REVENUE ANALYSIS FOR KEY PLAYERS IN THE CLOSED SYSTEM TRANSFER DEVICES MARKET IN THE PAST FIVE YEARS
12.4 MARKET SHARE ANALYSIS
12.4.1 CLOSED SYSTEM TRANSFER DEVICES MARKET (2020)
FIGURE 41 SHARE OF LEADING COMPANIES IN THE GLOBAL CLOSED SYSTEM TRANSFER DEVICES MARKET (2020)
TABLE 147 CLOSED SYSTEM TRANSFER DEVICES MARKET: DEGREE OF COMPETITION
12.5 R&D ASSESSMENT OF KEY PLAYERS
12.6 GEOGRAPHIC REVENUE ASSESSMENT OF KEY PLAYERS
12.7 COMPANY EVALUATION QUADRANT
12.7.1 COMPANY EVALUATION QUADRANT: CLOSED SYSTEM TRANSFER DEVICES MARKET
12.7.1.1 Stars
12.7.1.2 Pervasive players
12.7.1.3 Emerging leaders
12.7.1.4 Participants
FIGURE 42 CLOSED SYSTEM TRANSFER DEVICES MARKET: COMPANY EVALUATION MATRIX, 2020
12.8 COMPETITIVE BENCHMARKING
12.8.1 OVERALL COMPANY FOOTPRINT
TABLE 148 OVERALL COMPANY FOOTPRINT (20 COMPANIES)
TABLE 149 COMPANY FOOTPRINT: BY CLOSING MECHANISM (20 COMPANIES)
TABLE 150 COMPANY FOOTPRINT: BY TYPE (20 COMPANIES)
TABLE 151 COMPANY FOOTPRINT: BY COMPONENT (20 COMPANIES)
TABLE 152 COMPANY FOOTPRINT: BY TECHNOLOGY (20 COMPANIES)
TABLE 153 COMPANY FOOTPRINT: BY END USER (20 COMPANIES)
TABLE 154 COMPANY FOOTPRINT: BY REGION (20 COMPANIES)
12.9 COMPETITIVE SITUATIONS AND TRENDS
12.9.1 PRODUCT LAUNCHES & APPROVALS
TABLE 155 PRODUCT LAUNCHES & APPROVALS (2018–MAY 2021)
12.9.2 DEALS
TABLE 156 DEALS (2018–MAY 2021)
12.9.3 OTHER DEVELOPMENTS
TABLE 157 OTHER DEVELOPMENTS (2018–MAY 2021)
13 COMPANY PROFILES (Page No. - 181)
13.1 KEY PLAYERS
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
13.1.1 BECTON, DICKINSON AND COMPANY
TABLE 158 BD: BUSINESS OVERVIEW
FIGURE 43 BD: COMPANY SNAPSHOT
13.1.2 ICU MEDICAL
TABLE 159 ICU MEDICAL: BUSINESS OVERVIEW
FIGURE 44 ICU MEDICAL: COMPANY SNAPSHOT
13.1.3 EQUASHIELD
TABLE 160 EQUASHIELD: BUSINESS OVERVIEW
13.1.4 B. BRAUN MELSUNGEN
TABLE 161 B. BRAUN MELSUNGEN: BUSINESS OVERVIEW
FIGURE 45 B. BRAUN MELSUNGEN AG: COMPANY SNAPSHOT
13.1.5 JMS
TABLE 162 JMS: BUSINESS OVERVIEW
FIGURE 46 JMS: COMPANY SNAPSHOT
13.1.6 BAXTER INTERNATIONAL
TABLE 163 BAXTER INTERNATIONAL.: BUSINESS OVERVIEW
FIGURE 47 BAXTER INTERNATIONAL: COMPANY SNAPSHOT
13.1.7 SIMPLIVIA HEALTHCARE
TABLE 164 SIMPLIVIA HEALTHCARE: BUSINESS OVERVIEW
13.1.8 CORVIDA MEDICAL
TABLE 165 CORVIDA MEDICAL: BUSINESS OVERVIEW
13.1.9 YUKON MEDICAL
TABLE 166 YUKON MEDICAL: BUSINESS OVERVIEW
13.1.10 CODAN MEDIZINISCHE GERÄTE
TABLE 167 CODAN MEDIZINISCHE GERÄTE: BUSINESS OVERVIEW
13.1.11 VICTUS
TABLE 168 VICTUS: BUSINESS OVERVIEW
13.1.12 CARAGEN
TABLE 169 CARAGEN: BUSINESS OVERVIEW
13.2 OTHER PLAYERS
13.2.1 WEST PHARMACEUTICALS SERVICES
TABLE 170 WEST PHARMACEUTICALS SERVICES: BUSINESS OVERVIEW
FIGURE 48 WEST PHARMACEUTICAL SERVICES: COMPANY SNAPSHOT (2020)
13.2.2 VYGON SA
TABLE 171 VYGON: BUSINESS OVERVIEW
13.2.3 PRACTIVET
TABLE 172 PRACTIVET: BUSINESS OVERVIEW
13.2.4 CORNING INCORPORATED
TABLE 173 CORNING INCORPORATED: BUSINESS OVERVIEW
FIGURE 49 CORNING INCORPORATED: COMPANY SNAPSHOT (2020)
13.2.5 TERUMO CORPORATION
TABLE 174 TERUMO CORPORATION: BUSINESS OVERVIEW
FIGURE 50 TERUMO CORPORATION: COMPANY SNAPSHOT
13.2.6 CARDINAL HEALTH
TABLE 175 CARDINAL HEALTH: BUSINESS OVERVIEW
FIGURE 51 CARDINAL HEALTH: COMPANY SNAPSHOT
13.2.7 ERASER MEDICAL
TABLE 176 ERASER MEDICAL: BUSINESS OVERVIEW
13.2.8 INSUNG MEDICAL
TABLE 177 INSUNG MEDICAL: BUSINESS OVERVIEW
13.2.9 NEEDLELESS CORPORATION
13.2.10 ADVCARE MEDICAL
13.2.11 ELCAM MEDICAL
13.2.12 EPIC MEDICAL
13.2.13 EDGE PHARMA
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
14 APPENDIX (Page No. - 229)
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 AVAILABLE CUSTOMIZATIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
This study involved four major activities in estimating the current closed system transfer device market size. Extensive research was conducted to collect information on the market as well as its peer and parent markets. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the value market. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.
Secondary Research
This research study involved widespread secondary sources; directories; databases such as Bloomberg Businessweek and Factiva, white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for this extensive, technical, market-oriented, and commercial study of the closed system transfer devices market. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include CEOs, vice presidents, marketing and sales directors, marketing managers, regional/area sales managers, product managers, distributors, business development managers, technology and innovation directors of manufacturers, KOLs, and suppliers and distributors, whereas, the primary sources from the demand side include industry experts such as directors of hospitals and oncology centers/clinics, contract manufacturing organizations, nurses, pharmacists, and related key executives.
A breakdown of the primary respondents for closed system transfer device market (supply side) market is provided below:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The total size of the medical device contract manufacturing market was arrived at after data triangulation from three different approaches, as mentioned below.
Bottom-up Approach: The global market size for CSTDs was arrived at using the revenue share analysis of leading players in this market. Wherever feasible, the revenue share analysis was also employed to arrive at segmental market sizes by identifying leading players in respective product categories. For this purpose, major players in the market were identified through secondary research, and their revenues from the CSTDs business were determined through various insights gathered during the primary and secondary research.
Top-down approach: Individual shares of each segment were arrived at by assigning weightage based on their utilization rate and average selling price. The regional splits of the overall closed system transfer devices market and its subsegments are based on the adoption or utilization rates of the given products based on the availability of a product, the number of available products, and regulatory guidelines in respective regions or countries. For countries with limited availability of reliable and recent data, analogy/benchmarking-based market estimation and forecast technique was used.
Geographic Market Assessment: The geographic assessment was undertaken using the following approaches:
APPROACH 1: Geographic revenue contributions/splits of leading players in the market (wherever available), and respective growth trends
APPROACH 2: Geographic adoption trends for individual service offering segments and growth prospects for each of the segments (assumptions and indicative estimates validated from primary interviews).
Data Triangulation
After arriving at the market size, the total closed system transfer devices market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments & subsegments, data triangulation, and market breakdown procedures were employed, wherever applicable.
Approach to calculate the revenue of different players in the closed system transfer devices market
The size of the closed system transfer devices market was obtained from annual reports, SEC filings, online publications, and extensive primary interviews. A percentage split was applied to arrive at the size of market segments. Further splits were applied to arrive at the size for each sub-segment. Primary participants validated these percentage splits. The country-level market sizes obtained from the annual reports, SEC filings, online publications, and extensive primary interviews were added up to reach the total market size for regions. By adding up the market sizes for all the countries, the closed system transfer devices market was derived.
Approach to derive the market size and estimate market growth
The market size and market growth were estimated through primary interviews on a regional and global level. All responses were collated, and a weighted average was taken to derive a probabilistic estimate of the market size and growth rate.
Objectives of the Study
- To define, describe, and forecast the closed system transfer devices market based on type, component, closing mechanism, technology, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and industry-specific challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
- To forecast the size of the key regions in the closed system transfer devices market—North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To profile key players in the closed system transfer devices market and comprehensively analyze their core competencies2
- To track and analyze competitive developments such as product launches and approvals; acquisitions; expansions; and partnerships & agreements of the leading players in the closed system transfer devices market
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the present report:
Product Analysis
- Product matrix, which gives a detailed comparison of the product portfolios of each company
Geographic Analysis
- Further breakdown of the RoAPAC market into Australia, New Zealand, and others
- Further breakdown of the Latin American market into Brazil, Mexico, and the Rest of Latin America
Company Information
- Detailed analysis and profiling of additional market players (Up to 5)
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
SEND ME A FREE SAMPLE
Growth opportunities and latent adjacency in Closed System Transfer Devices Market
Which factors are playing vital role in growth of the Global Closed System Transfer Devices Market in different geographies?
What is the share of the top companies in the Global Closed System Transfer Devices Market?
Working on standardization in the field of Closed System Transfer Devices Market Segment Growth, Size, Share [2030]